MDB Capital Holdings, LLC reports developments as a public venture platform and investment holding company focused on launching and supporting disruptive technology companies. Its news commonly covers shareholder updates, operating results, portfolio-company positions, capital-market services and the activity of subsidiaries that combine broker-dealer, intellectual property and technology-development functions.
Company updates also feature PatentVest, MDB’s intellectual property intelligence, strategy and legal-services business. Recurring PatentVest releases discuss IP landscape reports, patent strategy, legal insights, biotechnology and medical-technology collaborations, and equity-linked service engagements that connect patent research, due diligence and venture formation.
Bio North Texas (MDBH) and PatentVest announced a multi-year strategic partnership to enhance the BioNTX Rising Stars life science platform in North Texas.
PatentVest will embed AI-enabled intellectual property (IP) strategy, structured IP diligence, and commercialization-focused portfolio assessments into Rising Stars, giving founders, investors, and judges deeper insight into startup IP assets. The collaboration is positioned as a model of strategic ecosystem partnership, emphasizing expert involvement over simple sponsorship visibility. It extends beyond the competition to include year-round engagement through educational programming, founder consultations, thought leadership, the iC³ Life Science & Healthcare Innovation Summit, and BioNTX Presents: Inside Innovation, all aimed at improving commercialization readiness and investment appeal for emerging life science and healthcare companies in the region.
PatentVest (NASDAQ:MDBH) released a new PV Pulse patent intelligence report titled “Who’s Actually Building the AI in AI Smart Glasses?”, analyzing validated patent activity across 12 companies involved in AI smart glasses, including current product makers, key component suppliers, and large tech firms without shipping products.
The report finds Apple and Microsoft hold some of the strongest AI-capability patent positions in the category, despite having no AI smart glasses on the market. Meta leads overall with about 1,900 patent families, Apple has an estimated 1,550, and Samsung’s often-cited 1,525-family count is reframed as closer to 550 validated glasses-system families for Samsung Electronics. Additional insights cover eight AI capability areas and portfolio maturity, including whether capabilities were built organically or via acquisition.
MDB Capital Holdings (NASDAQ: MDBH) reported operational highlights for the first six months of 2026, including serving as sole bookrunner and underwriter on the $20 million BUDA Juice IPO, joint bookrunner on the $15 million Ticketplus IPO, and completing a $5.9 million public offering for eXoZymes (NASDAQ: EXOZ).
MDB expanded its pipeline of early-stage disruptive companies, advanced discussions with potential MDB Direct/Public Ventures strategic partners, and prepared a spin-out of PatentVest as an independent public company. For the first half of 2026, MDB reported a net loss of approximately $16.1 million, fixed operating expenses of about $5 million, net cash used of about $3 million, and roughly $12.1 million in cash, current assets and marketable securities net of liabilities. Management will host a Zoom webinar on August 13, 2026, at 4:30 p.m. ET.
MDB Capital Holdings (NASDAQ: MDBH) will host a Zoom webinar on Thursday, August 13, 2026 at 4:30 p.m. Eastern Time to provide an operational update for the quarter ended June 30, 2026 and subsequent developments. A detailed press release will be issued before the call, which will be led by CEO and Co-Founder Christopher Marlett, potentially joined by other management members, and will include a Q&A session. Investors can pre-register for the webinar or access it live via MDB’s investor relations website.
MDB Capital Holdings (Nasdaq: MDBH), via its PatentVest division, released a new PatentVest Pulse report analyzing OpenAI's published patent portfolio and IP strategy as of July 2026. The study reviews 69 patent families (about 35 inventions) across 13 technology categories, distinguishing 49 internally developed families from 20 acquired through Rain Neuromorphics and Rockset.
The report maps OpenAI's patents to product areas including conversational AI, generative media, AI agents, developer platforms, personalization, and infrastructure for persistent digital work. It also examines citation relationships and compares OpenAI's IP approach with Microsoft, Google, IBM, and Anthropic to illustrate broader competitive positioning in generative AI.
PatentVest (NASDAQ:MDBH) released a new IP Legal Insights article titled “Why Patent Prosecution Is Ready for AI” on July 2, 2026. Written by patent attorney Michael Ohrenberger, it explains why patent prosecution is well suited for AI tools.
The piece discusses AI’s role in drafting, prior-art analysis, prosecution strategy, and portfolio management, emphasizing that technology should reduce repetitive work while experienced patent attorneys retain responsibility for strategic legal judgment and aligning IP with business objectives.
PatentVest (MDBH) released a new PatentVest Pulse report on how FGF21 is emerging as a key cardiometabolic layer beyond GLP-1 therapies.
The report reviews over $10.7 billion in recent acquisitions and licensing, competitive dynamics, and intellectual property shaping next‑generation obesity and cardiometabolic treatments.
PatentVest (MDBH) will present at Planet MicroCap Las Vegas on June 17 at 11:30 AM PT. The firm will cover intellectual property strategy, innovation intelligence, and AI-native IP services, including outcome-based patent prosecution and Examination-Upfront workflows aimed at stronger, more scalable patent portfolios.
PatentVest (NASDAQ:MDBH) released a new PatentVest Pulse report titled “The Muscle Problem: How Myostatin Could Expand the GLP-1 Opportunity.” The study analyzes 20 muscle-preservation programs aimed at improving body composition during GLP-1-based obesity treatment.
The report reviews myostatin inhibition, ActRII blockade, and GLP-1 combination strategies, plus related intellectual property, clinical pipelines, and major transactions such as Eli Lilly’s Versanis Bio deal and AstraZeneca’s SixPeaks Bio acquisition.
MDB Capital (NASDAQ: MDBH) will present at the Planet MicroCap Las Vegas 2026 conference, alongside subsidiary PatentVest and portfolio company Buda Juice (NYSE American: BUDA).
Executives will host live webcasts, Q&A sessions, and 1x1 investor meetings on June 17, 2026.